Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed (original) (raw)
Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn’s Disease and Ulcerative Colitis
Safa BOUJEMAA
Gastroenterology Research, 2023
View PDFchevron_right
Vedolizumab Trough Levels in Children with Anti-TNF Refractory Inflammatory Bowel Disease
Johanna Escher
Journal of Pediatric Gastroenterology & Nutrition, 2020
View PDFchevron_right
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
Gerassimos Mantzaris
Journal of Crohn's and Colitis, 2021
View PDFchevron_right
Prophylactic Treatment with Vedolizumab in the Prevention of Postoperative Recurrence (POR) in High-Risk Crohn’s Patients
Sara Frassino
Journal of Clinical Medicine, 2023
View PDFchevron_right
Pharmacogénétique de l’infliximab dans la maladie de Crohn
Vinciane Dideberg
Acta Endoscopica, 2007
View PDFchevron_right
Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-α drug failure
Mariam Aguas
Digestive and Liver Disease
View PDFchevron_right
Addition of an immunomodulator as a rescue therapy for loss of response to adalimumab dose escalation in patients with Crohn's disease
Gerassimos Mantzaris
Journal of Crohn's & colitis, 2015
View PDFchevron_right
When to use biological agents in inflammatory bowel disease
Rupert Leong
Journal of Gastroenterology and Hepatology, 2012
View PDFchevron_right
What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
Gökhan Kabaçam
The Turkish Journal of Gastroenterology, 2010
View PDFchevron_right
Biologic Therapies for Inflammatory Bowel Diseases
Vassilis Valatas
2013
View PDFchevron_right
Review of the safety with biologics in inflammatory bowel disease
Santiago García-lópez
Journal of IMIDs
View PDFchevron_right
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
Philippe Van Hootegem
The Lancet, 2008
View PDFchevron_right
Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
Satoshi Motoya
Journal of Gastroenterology, 2019
View PDFchevron_right
Inflammatory Bowel Disease. From Bench to Bedside
Fergus Shanahan
Digestive and Liver Disease, 2004
View PDFchevron_right
Arthritis or vasculitis as presenting symptoms of Crohn’s disease
Ori Segol
Rheumatology International, 2005
View PDFchevron_right
Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study
Yi-jen Fang
Intestinal Research, 2014
View PDFchevron_right
Evaluation of inflammatory activity in Crohn’s disease and ulcerative colitis
Maria de Lourdes Abreu Ferrari
World Journal of Gastroenterology, 2012
View PDFchevron_right
Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study
Csaba Dr Balázs
BMC Gastroenterology, 2009
View PDFchevron_right
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Ida Hilmi
New England Journal of Medicine, 2013
View PDFchevron_right
Treatment Persistence for Infliximab Versus Adalimumab in Crohnʼs Disease
Pablo Olivera
Inflammatory Bowel Diseases, 2017
View PDFchevron_right
Su1971 REAL-WORLD EFFECTIVENESS AND SAFETY OF USTEKINUMAB FOR THE TREATMENT OF CROHNS DISEASE: THE SCOTTISH USTEKINUMAB COHORT
jonathan macdonald
Gastroenterology, 2020
View PDFchevron_right
Mo1865 - Ustekinumab Induces Clinical and Biological Remission in Biologic Refractory Crohn's Disease Patients: A Real World Belgian Cohort Study
Philippe Van Hootegem
Gastroenterology, 2018
View PDFchevron_right
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response
Antonio Lopez-sanromán
Gastroenterología y Hepatología, 2008
View PDFchevron_right
Retreatment and maintenance therapy with infliximab in fistulising Crohn's disease
ruth de francisco
Gastroenterology, 2003
View PDFchevron_right
Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease
Andrew Macpherson
Pharmaceuticals, 2010
View PDFchevron_right
Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Alan Lobo
PharmacoEconomics, 2016
View PDFchevron_right
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Hicham El Ossmani
The Lancet Gastroenterology & Hepatology, 2019
View PDFchevron_right
Serum protein profile of Crohn's disease treated with infliximab
Gerassimos Mantzaris
Journal of Crohn's and Colitis, 2013
View PDFchevron_right
Vedolizumab in Ulcerative Colitis and Crohn's Disease-A Systematic Review
Journal of Pharmaceutical Research Science & Technology
INTERNATIONALE PHARMACEUTICA SCIENCIA, 2021
View PDFchevron_right
Inflammatory Bowel Disease: the Pathologists Approach to the Clinical Problem
Emil Salmo
Inflammatory Bowel Disease and Familial Adenomatous Polyposis
View PDFchevron_right
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
Carmen Stefanescu
Clinical Gastroenterology and Hepatology, 2016
View PDFchevron_right
Induction Therapy With Biosimilar Infliximab in Children With Crohn Disease
Rizal Ardiansyah
Journal of Pediatric Gastroenterology & Nutrition, 2017
View PDFchevron_right
Cholestasis associated with mesalazine therapy in a patient with Crohn's disease
Tilman Sauerbruch
Journal of Hepatology, 1997
View PDFchevron_right
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases
Monika Fischer
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2018
View PDFchevron_right
Crohn’s disease in women
Ivana Plavsic
International Journal of Women's Health, 2013
View PDFchevron_right